Skip to content
Menu

B. Riley Securities Reiterates Buy on Journey Medical, Lowers Price Target to $13

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and lowers the price target from $15 to $13.

B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and lowers the price target from $15 to $13.

Read at benzinga.com